Related content

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

By Wu Jie   Zhu Yiqing   Jiang Yunfei   Cao Yaoping  

Gynecological Endocrinology, Vol. 24, Iss. 7, 2008-01 ,pp. : 392-398

Informa Healthcare

Access to resources Recommend Favorite

Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance

By Lemay A.   Dodin S.   Turcot L.   Déchêne F.   Forest J-C.  

Human Reproduction, Vol. 21, Iss. 1, 2006-01 ,pp. : 121-128

Oxford University Press

Access to resources Recommend Favorite

Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment

By Luboshitzky R.   Shen-Orr Z.   Herer P.   Nave R.  

Gynecological Endocrinology, Vol. 17, Iss. 6, 2003-12 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

By Elter Koray   Imir Gonca   Durmusoglu Fatih  

Human Reproduction, Vol. 17, Iss. 7, 2002-07 ,pp. : 1729-1737

Oxford University Press

Access to resources Recommend Favorite

Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin

By Luque-Ramrez Manuel   lvarez-Blasco Francisco   Uriol Rivera Miguel Giovanni   Escobar-Morreale Hctor F.  

Human Reproduction, Vol. 23, Iss. 7, 2008-07 ,pp. : 1594-1601

Oxford University Press

Access to resources Recommend Favorite